Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (726)	7/22/2003 1:05:31 PM
From: keokalani'nui	Respond to of 2240

Roche Buys Rights To Cardion's IL-15 Antagonist Tuesday July 22, 2:51 am ET BASEL -(Dow Jones)- Swiss pharmaceutical company Roche Holding AG said Tuesday it acquired the rights to Cardion AG's IL-15 antagonist to strengthen its rheumatoid arthritis and transplantation franchise. The compound is currently at preclinical stage as a treatment for rheumatoid arthritis and transplantation. Cardion, which is based in Germany, will receive an initial payment, as well as additional milestone-based payments that could reach up to $90 million if all development event milestones are met, Roche said. On top of that, Roche would pay Cardion royalties based on future product sales. "These substances represent innovative therapies to treat these diseases and will consolidate Roche's position in these key medical areas," said William M. Burns, head of Roche's pharmaceuticals division. Rheumatoid arthritis, or RA, is a chronic autoimmune disease, which affects almost 6 million people around the world. It is a debilitating disease that hinders the daily activities of sufferers. Roche also is developing its top-selling cancer medicine, MabThera, for the treatment of RA. MabThera is currently indicated for use in the treatment of the most common form of blood cancer, non-Hodgkin's lymphoma, or NHL. The Swiss pharmaceutical company also has several transplantation drugs on the market, or in the pipeline. Among them are CellCept, the largest-selling branded immunosuppressive in North America and Zenapax, which prevents the acute rejection of a newly transplanted organ.

To: Icebrg who wrote (726)	7/25/2003 3:29:10 AM
From: Icebrg	Respond to of 2240

Denmark's Genmab Issues Shares Worth About DKK13 Million Friday July 25, 3:11 am ET COPENHAGEN -(Dow Jones)- Danish bitotechnology company Genmab A/S will be issuing shares worth around 13 million kroner to GenPharm International, a subsidiary of Genmab's major shareholder Medarex Inc. (NasdaqNM:MEDX - News) in the U.S, as part of previously-announced payments to Medarex for rights to market certain technologies. Genmab announced Friday that its board of directors has adopted a resolution to increase the companys share capital by 246,914 shares to a total of 22,963, 534 shares. All shares are offered to and subscribed by GenPharm International, Inc. at a price of DKK 52.5 per share of DKK 1 and are issued without any preemption rights for the other shareholders of the company or others. The new shares will in all respects carry the same rights as the existing shares in Genmab A/S. GenPharm International, Inc. is a wholly owned subsidiary of Medarex, Inc. The shares are issued pursuant to a Genomics agreement entered into with Medarex, Inc. on 26 August 2000 (as amended). Under the terms of the Genomics agreement Genmab received the exclusive rights to market the transgenic mouse technologies for multi-target (five or more targets) European genomics partnerships. In addition, the Genomics Agreement granted Genmab certain rights to access technologies acquired by Medarex, Inc., from Biosite Diagnostics Incorporated and Kirin. Genmab is obligated to pay Medarex, Inc. USD 2 million per year for the Genomics agreement up to and including 2004. However, Genmab has the option to pay these amounts in either cash or shares in Genmab A/S. Accordingly, Genmab A/S has exercised its option to pay an amount of USD 2 million that would otherwise become payable in cash, through the issue of shares to GenPharm International, Inc. The subscription price has been agreed as the market price of Genmab A/S shares as listed on the Copenhagen Stock Exchange at close of business July 24, 2003 calculated on the basis of the official exchange rate of the Danish Central Bank on July 24, 2003 which was USD 1 = DKK 6,4815. Genmab intends to use the USD 2 million saved in cash for general research and development purposes. Following the issue Medarex, Inc. will own through GenPharm International, Inc., a total of 7,352,104 shares in Genmab A/S corresponding to 32 percent of the shares in Genmab A/S. The issue will be effected on the basis of an exemption from any prospectus requirements.